Familial partial lipodystrophy

Familial partial lipodystrophy
Other names: FPLD[1]

Familial partial lipodystrophy, also known as Köbberling–Dunnigan syndrome,[2] is a rare genetic metabolic condition characterized by the loss of subcutaneous fat.[3]: 495 

FPL also refers to a rare metabolic condition in which there is a loss of subcutaneous fat in the arms, legs and lower torso. The upper section of the body, face, neck, shoulders, back and trunk carry an excess amount of fat.

As the body is unable to store fat correctly this leads to fat around all the vital organs and in the blood (triglycerides). This results in heart problems, cirrhosis of the liver, lipoatrophic diabetes, and pancreatitis, along with various other complications.

Types

OMIM Name Locus
608600 FPLD1 (Kobberling-type, loss from extremities)  ?
151660 FPLD2 (Dunnigan-type, loss from limbs and trunk) LMNA; 1q21.2
604367 FPLD3 PPARG; 7q11.23-q21.11, 3p25

Signs and symptoms

Type 1 is believed to be underdiagnosed.[4]

Genetics

DNA Sanger sequencing analysis of the LMNA gene, within ex. 8 the single nucleotide substitution C > T in one LMNA allele has been identified which is related to occurrence of p.Arg482Trp mutation

A mutations in a number of genes have been associated with this condition. Mutations associated with FPL have been reported in LMNA (lamin A/C), PPARG (PPARγ), AKT2 (AKT serine/threonine kinase 2), PLIN1 (perilipin-1), and CIDEC (cell-death-inducing DFFA-like effector B).[5]

Six types (1-6) have been described. Types 1-5 are inherited in an autosomal dominant fashion.


Type 1 (Kobberling variety, FPL1) is very rare and has only been reported in women to date. Fat loss is confined to the limbs and mostly in the distal parts. Central obesity may be present. Complications include hypertension, insulin resistance and hypertriglyceridemia. The gene causing this condition is not yet known. This form was first described in 1975.

Type 2 (Dunnigan Variety, FPL2) is the most common form and is due to mutations in the LMNA gene. Over 500 cases have been reported to date. Development up to puberty is normal. Fat is then gradually lost in is the limbs and trunk. Fat may accumulate around the face and between the shoulder blades. Insulin resistance is common. Other conditions associated with this condition include acanthosis nigricans, fatty liver, hypertriglyceridemia and polycystic ovary syndrome in women. There is an increased risk of coronary heart disease. Cardiomyopathy and muscular dystrophy may occur rarely. Xanthoma and nail changes may occur.

Type 3 is due to mutations in the PPARG gene. It is rare with approximately 30 cases reported to date. It is similar to type 2 but tends to be milder.

Type 4 is due to mutations in the PLIN1 gene. It is rare with only a small number of cases reported. Fat loss tends to affect the lower limbs and buttocks. Insulin resistance and hypertriglyceridemia occur. Calf muscular hypertrophy may occur.

Type 5 is due to mutations in the AKT2 gene. It has been reported in four patients all members of the same family. Fat loss affects the upper and lower limbs. The patients also had hypertension, insulin resistance and hypertriglyceridemia.

Type 6 due to mutations in the CIDEC gene. It is inherited in an autosomal recessive fashion and has been reported in only one patient to date. Features included fat loss, severe insulin resistance, fatty liver, acanthosis nigricans and diabetes.

Another gene that has been associated with this condition is AGPAT2.[6]

Diagnosis

In terms of the diagnosis for Familial partial lipodystrophy we find the following:[7]

  • Clinical exam
  • MRI
  • CT-scan
  • Whole-body dual-energy X-ray absorptiometry
  • CBC

Treatment

The treatment for this condition consists of the following:[7]

  • Monitoring diet
  • Daily physical activity
  • Statins, or fibrates
  • Metreleptin (in Europe )

Prevalence

This not known with certainty but is estimated to be about one per million. It appears to be more common in females than males.

See also

References

  1. ↑ "Orphanet: Familial partial lipodystrophy". www.orpha.net. Archived from the original on 4 October 2022. Retrieved 27 April 2019.
  2. ↑ Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. pp. 1541–2, 1543. ISBN 978-1-4160-2999-1.
  3. ↑ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 978-0-7216-2921-6.
  4. ↑ Herbst KL, Tannock LR, Deeb SS, Purnell JQ, Brunzell JD, Chait A (June 2003). "Köbberling type of familial partial lipodystrophy: an underrecognized syndrome". Diabetes Care. 26 (6): 1819–24. doi:10.2337/diacare.26.6.1819. PMID 12766116. Archived from the original on 2013-04-15. Retrieved 2022-06-30.
  5. ↑ Garg A (2011). "Clinical review#: Lipodystrophies: genetic and acquired body fat disorders". J. Clin. Endocrinol. Metab. 96 (11): 3313–25. doi:10.1210/jc.2011-1159. PMC 7673254. PMID 21865368.
  6. ↑ Broekema MF, Massink MPG, De Ligt J, Stigter ECA, Monajemi H, De Ridder J, Burgering BMT, van Haaften GW, Kalkhoven E (2018) A single complex Agpat2 allele in a patient With partial lipodystrophy. Front Physiol 9:1363. doi: 10.3389/fphys.2018.01363.
  7. 1 2 RESERVED, INSERM US14-- ALL RIGHTS. "Orphanet: Familial partial lipodystrophy". www.orpha.net. Archived from the original on 4 October 2022. Retrieved 4 October 2022.
Classification
External resources
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.